FDA asks drugmaker to stop selling its opioid painkiller


The Food and Drug Administration said Thursday it has asked Endo Pharmaceuticals to stop selling its reformulated, extended-release painkiller, Opana ER. Endo had touted the new formulation as abuse-resistant, though the FDA did not allow the company to market it as such when granting approval for sales several years ago.



from Biotech News